Identification and Control of Critical Process Points Using Complementary Risk Assessments (corrected)

Similar documents
Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM

The Bacterial Endotoxins Test:

Quality Risk Management

Paradigm Change in Manufacturing Operations SM

Quality Risk Management & food safety management

CGMP for 21 st Century : A Risk-based Approach (Quality by Design)

Preparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014

Systematic Risk Management: An Overview of ICH Q-9

Risk Analysis: myths, confusions and real sense

Aseptic Sampling Best Practices Endotoxin Binding Affinity

Custom processing services

Opportunities, Challenges and Benefits of using HACCP as a Quality Risk Management Tool in the Pharmaceutical Industry

Practical Strategies for Improving Quality Risk Management activities in GMP environments

Whitepaper. High temperature HEPA filtration. Dr.-Ing. Marc Schmidt, Dr.-Ing. Lothar Gail, Hugo Hemel MSc. Preview

Application of Quality Risk Management Tools for Cell Therapy Manufacturing

Dealing with chance Four strategies. Simple, direct Absolutes. Persuasion Top management support. Training. Corruption Alienation. 3 lines of defense

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Complaints Investigations Root Cause Analysis

RISK MANAGEMENT. ASQ Orange Empire Section 2017 Quality Day

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides

RISK ASSESSMENT IN PHARMACEUTICAL MICROBIOLOGY

Quality Risk Management (QRM) of active pharmaceutical ingredients during transportation by using FMEA tools and methodology

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

MASTER PLANNING FOR VALIDATION

Critical Environment Products and Services

FMEA Failure Mode Effects Analysis. ASQ/APICS Joint Meeting May 10, 2017

Risk Management: FDA and Industry Experience. Dan Snider, Ph.D Vice President Morgantown RD Mylan Pharmaceuticals Inc.

Risk Based Validation. Why, How and with what tools?

QUALITY AGREEMENT. The following Agreement has been concluded between

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>

PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland

Using risk management tools to manage the integrity of the cold chain

Ben Venue Laboratories, Inc. 16-Nov-07

White Paper. Risk Management in Environmental Monitoring: Should you be spotting it sooner?

Lifecycle Product Quality Risk Management

Library Guide: Active Pharmaceutical

THE BASIC PRINCIPLES OF HACCP

Pharmaceutical cgmps for the 21st Century February 2004

Equipment Risk Management

Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines

How to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant

Testo Expert Knowledge. The GxP Dictionary 1st edition. Definitions relating to GxP and Quality Assurance

Elemental Impurities: An Industry Perspective

Documenta tion and Records

Overview Engineering Unit

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

Metrics in Microbiology Monitoring Practices

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel

for IND and RDRC Regulated PET Compounding

2. Risk-based compliance was also a key component in the FDA's new approach for dealing with electronic records and signatures: 21 CFR Part 11.

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Process development and basic GMP

Efficient Validation Strategies and VMPs

Compounding Pharmacies and the Contract Testing Lab

How to Select a Microbiology Contract Testing Laboratory? Tony Cundell, Ph. D. Microbiological Consulting, LLC Scarsdale, New York

Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets

Laboratory OOS Investigations The Missing Link

A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products

MFA Inc Compliance with the Food Safety Modernization Act. Jim S White PhD Director, Livestock Nutrition MFA Inc Columbia, MO

Risk Management ICH Q9 - FMEA - Applied to Validation

Hazard Analysis and Critical Control Point The Almond Board of California. Overview. Definitions

Manual 058 Out of Specification Results Investigation

At Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

CMC Strategy Forum Europe 2016

Q & A on USP General Chapter <823> Revision Proposal Webinar held on 21 February 2011

Supplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan

Quality by Design in Critical Filtration Operations

Lessons from Pharmaceutical Laboratory related FDA Warning Letters

HUMAN FACTORS ENGINEERING: DESIGN OF MEDICAL DEVICES

WHO guidelines on quality risk management

In recent years formal process risk

Overview of Inspection Issues with Legacy Products

FSMA Food Safety Seminar Japan External Trade Organization

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

On-Site GMP Training GMP COMPLIANCE TECHNICAL

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A

Introduction and Background

Overview of Regulatory Requirements for API and Formulations

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

HACCP audit checklist

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A

Improvement of the robustness of the purification process of the intravenous immunoglobulin product (10%) Gammagard Liquid/Kiovig

EU Guidance / Q&A. Greg McGurk, GMP Manager (acting) GMP Conference. 7 February 2017 Dublin

GMP Track 1 Day 2 Session 1 Vendor Assurance

The ABCs and Challenges of GMP The American Experience

Reference Standard Characterization. Steve Lane. General Manager, NSF Reference Standards.

FlexAct BT (Bag Tester) Flexboy 2D November, 2015

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

Inspections, Compliance, Enforcement, and Criminal Investigations

Auditing Your Laboratory for Compliance with the FDA Dietary Supplement GMP s

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

Prevent Quality System Deficiencies by Conducting Effective Internal Audits. Whitepaper

PyroSense PAT for WFI By Ken Nichols and Maribeth Donovan Janke

Microbiology Research Associates

Elemental impurities impact on APIs

The best just got better!

Drug Good Manufacturing Practices Inspections

Risk based approaches for a sterility assurance application review: a microbiologist s perspective Dr. Yeissa Chabrier Roselló

Transcription:

Identification and Control of Critical Process Points Using Complementary Risk Assessments (corrected) Karen McCullough MMI Associates (908) 534-6463 PDA Metro Chapter Day June 2, 2009

RISK is a four letter word Over-encouraged Over-exposed Misunderstood Misapplied The process is subject to unfounded assumptions and opinion to influence the result

Pre-emptive Risk When is the best time to assess risk? Before a failure occurs! Objective Unemotional When is the worst time to assess risk? Before a bad decision is made After a bad decision is made Pressure to come to a certain conclusion

GMP and Standards References Guidance for Industry: Q9 Quality Risk Management http://www.fda.gov/cder/guidance/7153fnl.htm Pharmaceutical cgmps for the 21st Century: A Risk Based Approach ISO 14971:2007, Medical devices - application of risk management to medical devices

Getting Started Identify and assemble a cross functional team Describe/understand the product, its formulation and its distribution Identify and understand the intended use and quality attributes of the product Develop a flow diagram that describes the process Understand processing methods

Risk Assessment 1: HACCP Hazard Analysis and Critical Control Point Pillsbury created HACCP in the 1960s as a process control mechanism for food for NASA FDA adopted HACCP as a requirement for process control in the food industry Hazard Analysis and Critical Control Point Principles and Application Guidelines, August 1997, http://www.cfsan.fda.gov/~comm/nacmcfp.html HACCP identified as a risk assessment tool in FDA, ISO, ICH and WHO documents

HACCP: 7 Steps 1. Conduct a Hazard Analysis 2. Determine the critical control points (CCP) 3. Establish critical limits 4. Establish monitoring procedures 5. Establish corrective actions 6. Establish verification procedures 7. Establish record-keeping and documentation procedures

1. Hazard Analysis Identify all of the potential hazards Hazard is defined as any condition that results in an adverse consequence detrimental to the patient or product. Common hazards for all parenterals are Non sterility Endotoxin (pyrogen) in excess of the limit For our discussion, the Hazard is endotoxin in excess of the limit, and the adverse consequence (harm to the patient) is fever or maybe even death.

2. Determine the CCP Critical Control Point = step at which control can be applied and is essential to prevent or eliminate an identified hazard or reduce it to an acceptable level CCPs are hazard-specific. Not all hazards have the same critical control points Example: 0.2µm filters remove microorganisms, but do not eliminate free endotoxin. So, a product can be sterile but still contain a high level of endotoxin Decision Trees provide a consistent and unbiased way of identifying CCP

Process Map WFI Receive Components Raw Materials and API Receipt and Testing Formulation in SS tanks Depyro vials Depyro stoppers Sterile filter Ultrafilter Fill Test

Decision Tree for HACCP Does this step involve a hazard or significant risk or severity to warrant its control? Does a preventive measure for the hazard exist at this step? Not a CCP Is control at this step necessary to prevent, eliminate, or reduce the hazard to the patient? Is control at this step necessary for safety? Modify the step, CCP Not a CCP process or product Not a CCP

Which Steps or Components are CCP? WFI Receive Components Raw Materials and API Receipt and Testing Formulation in SS tanks Depyro vials Depyro stoppers Sterile filter Ultrafilter Fill Test

Depyrogenation Example Does this step involve a hazard or significant risk or severity to warrant its control? Does a preventive measure for the hazard exist at this step? Not a CCP Is control at this step necessary to prevent, eliminate, or reduce the hazard to the patient? Is control at this step necessary for safety? Modify the step, CCP Not a CCP process or product Not a CCP

Sterilization Filter Example Does this step involve a hazard or significant risk or severity to warrant its control? Does a preventive measure for the hazard exist at this step? Not a CCP Is control at this step necessary to prevent, eliminate, or reduce the hazard to the patient? Is control at this step necessary for safety? Modify the step, CCP Not a CCP process or product Not a CCP

Testing Example Does this step involve a hazard or significant risk or severity to warrant its control? Does a preventive measure for the hazard exist at this step? Not a CCP Is control at this step necessary to prevent, eliminate, or reduce the hazard to the patient? Is control at this step necessary for safety? Modify the step, CCP Not a CCP process or product Not a CCP

Laboratory Testing False Negatives might release a lot that is harmful to patients Patient risk Compliance risk Business risk False Positives might destroy a lot that is perfectly fine Business risk

What can go wrong at each CCP? Risk Assessment 2: FMEA Failure Mode and Effect Analysis Analysis of each identified CCP Failure Mode - What can go wrong? Potential effect of failure - What is the consequence of the failure? Potential causes of the failure - Why would the failure happen? Assign numerical ratings for: Severity Occurrence Detection

Note Added: The question was asked at the Chapter Day Meeting regarding FMEA as my choice for Assessment #2. Any risk method can be used (HACCP, fault tree, fish bone, etc). I chose FMEA because the RPN number allows me to rank the failure modes and concentrate on those that pose a real threat to the integrity of the testing lab and the resulting data.

Risk Ratings Severity Occurrence Detection 1 2 3 Failure would likely not be noticeable in the final product Failure could increase trendline for final product endotoxin Failure could cause patient injury 1 2 3 Failures are rare Failures are occasional Failure is likely to occur 1 2 3 Detection of a failure is certain Step is monitored intermittently Step is not tested or monitored Best Worst

FMEA Cross-functional team must consider each potential failure mode for severity, occurrence, detection, and assign Calculate RPN (Risk Priority Number) by multiplying ratings for severity, occurrence and detection Consider mitigations Re-assign ratings Re-calculate RPN

Sample FMEA Template FMEA Process Action Results Item and Function Potential Failure Mode Potential Effect(s) of Failure Severity Potential Cause(s) of Failure Occurrence Current Controls Detection RPN Recommended Action Action Taken Severity Occurrence Detection RPN

FMEA Process: Testing (Not Exhaustive) Action Results Item and Function Potential Failure Mode Potential Effect(s) of Failure Severity Potential Cause(s) of Failure Occurrence Current Controls Detection RPN Recommended Action Action Taken Severity Occurrence Detection RPN Positive Product Control - Inhibition Standard curve - kinetic test Depyrogenation Platicware used in sample prep/standard series Sampling of test material PPC Does not react Standard curve is OOT Endotoxin in sample Endotoxin in sample Sample contaminated invalid test overestimation of endotoxin Underestimation of endotoxin False positive False positive False positive 1 1 1 1 Inhibitory product Spike incorrectly prepared Reagent not stored properly Pipettors not calibrated 2 Validation 1 2 Receive CC Notifications Get on list 1 2 1 2 1 Training 2 2 None NA NA NA NA NA 1 1 Qualified Storage Pipettors on schedule 2 1 3 6 Standard curve Training impoperly prepared 3 2 3 18 2 2 Glassware contributes endotoxin Plasticware contributes endotoxin 1 Validated cycle; review of charts 2 None 3 12 2 Human error 2 Training 3 12 2 Plasticware contributes endotoxin 2 None 3 12 1 1 None NA NA NA NA NA 2 2 None NA NA NA NA NA Trend standard curve parameters Trend standard curve parameters 2 1 1 2 3 1 1 3 1 2 None NA NA NA NA NA Institute screening per USP Regular observation Institute screening per USP Trend onset times, slope, intercept Test plastic as device Observation schedule Test plastic as device 2 1 1 2 2 1 1 2 2 1 1 2

3. Establish Limits for Each CCP What attributes need monitoring? What are the limits for or expectations for those attributes? For the lab example Standard curves Depyrogenation processes Equipment IOPQ Screening of plasticware

Standard Curve OD Log 10 onset time Time Log 10 endotoxin

4. Establish Monitoring Procedures Lay out/justify monitoring plans Describe analysis of monitoring data - tracking/trending. For the testing example: Screen plasticware as medical devices Trend standard curves Monitor depyrogenation processes and refrigerator/freezer temperatures Assure re-validation if required (follow change control) Provide continuing training

5. Establish Corrective Actions What could go wrong, and how might we mitigate or correct it? Problems may be anticipated and mitigations suggested by the FMEA tool

6. Establish Verification Procedures Write SOPs Validate methods and processes Calibrate/qualify equipment Training

7. Establish Documentation Is there a provision for the recording of all essential information? Where do we go for records? Routine monitoring PM Validation data Calibration Are records complete?

Extra Added Bonus!!!!! Go through the FMEA and make a list of the potential causes for the failure and the mitigation This list is the basis for your checklist if/when you have an OOS that needs investigation!

Summary Any analysis, including the various risk analyses are, to some extent, subjective Cross functional team makes the rules to: Reduce bias Guarantee consistency Once the rules are made, the identification of CCP and Failure Modes becomes relative to the process under study and the rules of the team Identify and mitigate risk for CCP

Thank you! Karen McCullough MMI Associates karenzm@embarqmail.com